A prospective study to evaluate the efficacy and adverse effects of alpha-blockers in the management of benign prostatic hyperplasia

Conclusion: The obtained results showed that both silodosin and tamsulosin produced significant improvement in IPSS and quality of Life in BPH patients. BPH is a nonemergency medical condition, during COVID pandemic situation outpatient visit to hospitals were postponed or cancelled, even if they struggle with troublesome urinary symptoms and unavoidable impact on quality of life. [...]the need for medical management for symptomatic relief of BPH increased. Exclusion Criteria The following criteria were excluded from the study: * Prostate carcinoma. * Concomitant HIV, HBV or HCV infection. * Renal failure. * Liver disease. * Recent cataract surgery. * Psychiatry disorders.